With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is ₺1.828,29, with a 24-hour trading volume of ₺33,79B. The asset's market cap is ₺8,1T, after moving 0.13% in the last day.
Tokenized Novo Nordisk A/S is trading at ₺1.822,11, with a tokenized market cap of ₺148,09M and a 24-hour trading volume of ₺37,92M. The tokenized asset has moved 3.80% in the past 24 hours.